Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Feb;55(2):243-51.
doi: 10.1136/gut.2004.059741. Epub 2005 Jun 28.

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

J Schirra  1 , M Nicolaus, R Roggel, M Katschinski, M Storr, H J Woerle, B Göke
Affiliations

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

J Schirra et al. Gut. 2006 Feb.

Abstract

Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1) lowers glycaemia by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying.

Aims: To assess the effects of endogenous GLP-1 on endocrine pancreatic secretion and antro-pyloro-duodenal motility by utilising the GLP-1 receptor antagonist exendin(9-39)amide (ex(9-39)NH2).

Methods: Nine healthy volunteers underwent four experiments each. In two experiments with and without intravenous infusion of ex(9-39)NH2 300 pmol/kg/min, a fasting period was followed by intraduodenal glucose perfusion at 1 and 2.5 kcal/min, with the higher dose stimulating GLP-1 release. Antro-pyloro-duodenal motility was measured by perfusion manometry. To calculate the incretin effect (that is, the proportion of plasma insulin stimulated by intestinal hormones) the glycaemia observed during the luminal glucose experiments was mimicked using intravenous glucose in two further experiments.

Results: Ex(9-39)NH2 significantly increased glycaemia during fasting and duodenal glucose. It diminished plasma insulin during duodenal glucose and significantly reduced the incretin effect by approximately 50%. Ex(9-39)NH2 raised plasma glucagon during fasting and abolished the decrease in glucagon at the high duodenal glucose load. Ex(9-39)NH2 markedly stimulated antroduodenal contractility. At low duodenal glucose it reduced the stimulation of tonic and phasic pyloric motility. At the high duodenal glucose load it abolished pyloric stimulation.

Conclusions: Endogenous GLP-1 stimulates postprandial insulin release. The pancreatic alpha cell is under the tonic inhibitory control of GLP-1 thereby suppressing postprandial glucagon. GLP-1 tonically inhibits antroduodenal motility and mediates the postprandial inhibition of antral and stimulation of pyloric motility. We therefore suggest GLP-1 as a true incretin hormone and enterogastrone in humans.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Comment in

References

    1. Kreymann B, Williams G, Ghatei M A.et al Glucagon‐like peptide‐1 7‐36: a physiological incretin in man. Lancet 198721300–1304. - PubMed
    1. Komatsu R, Matsuyama T, Namba M.et al Glucagonostatic and insulinotropic action of glucagonlike peptide I‐(7‐36)‐amide. Diabetes 198938902–905. - PubMed
    1. Schirra J, Leicht P, Hildebrand P.et al Mechanisms of the antidiabetic action of subcutaneous glucagon‐like peptide‐1(7‐36)amide in non‐insulin dependent diabetes mellitus. J Endocrinol 1998156177–186. - PubMed
    1. Schirra J, Kuwert P, Wank U.et al Differential effects of subcutaneous GLP‐1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 199710984–97. - PubMed
    1. Schirra J, Wank U, Arnold R.et al Effects of glucagon‐like peptide‐1(7‐36)amide on motility and sensation of the proximal stomach in humans. Gut 200250341–348. - PMC - PubMed

Publication types

MeSH terms